Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
“The randomised control trial (RCT) – the ‘gold standard’ for clinical evidence.
If that is so, why is all evidence not gathered in such a manner.
For those in research, the answer is evident but doctors and scientists forget that the complexities of the nuts and bolts of a quality trial are not common knowledge of our patients.
Not all questions can be answered with an RCT, not to mention the cost in setting one up.
Trials with mild or moderate methodological failing or negative results may not even get published, with the hard work never known outside the investigating team.
For anyone who wanted a quick overview of RCTs but was a little afraid or embarrassed to ask, here is a quick video for you.”
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis